Poveda, A.; Lopez-Reig, R.; Oaknin, A.; Redondo, A.; Rubio, M.J.; Guerra, E.; Fariñas-Madrid, L.; Gallego, A.; Rodriguez-Freixinos, V.; Fernandez-Serra, A.;
et al. Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers 2022, 14, 915.
https://doi.org/10.3390/cancers14040915
AMA Style
Poveda A, Lopez-Reig R, Oaknin A, Redondo A, Rubio MJ, Guerra E, Fariñas-Madrid L, Gallego A, Rodriguez-Freixinos V, Fernandez-Serra A,
et al. Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers. 2022; 14(4):915.
https://doi.org/10.3390/cancers14040915
Chicago/Turabian Style
Poveda, Andres, Raquel Lopez-Reig, Ana Oaknin, Andres Redondo, Maria Jesus Rubio, Eva Guerra, Lorena Fariñas-Madrid, Alejandro Gallego, Victor Rodriguez-Freixinos, Antonio Fernandez-Serra,
and et al. 2022. "Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study" Cancers 14, no. 4: 915.
https://doi.org/10.3390/cancers14040915
APA Style
Poveda, A., Lopez-Reig, R., Oaknin, A., Redondo, A., Rubio, M. J., Guerra, E., Fariñas-Madrid, L., Gallego, A., Rodriguez-Freixinos, V., Fernandez-Serra, A., Juan, O., Romero, I., & Lopez-Guerrero, J. A.
(2022). Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers, 14(4), 915.
https://doi.org/10.3390/cancers14040915